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Because of the rarity of neuroblastoma and poor survival until the 1990s, information on late effects in neuroblastoma survivors is
sparse. We comprehensively reviewed the long-term risk for somatic disease in neuroblastoma survivors. We identiﬁed 721 5-year
survivors of neuroblastoma in Nordic population-based cancer registries and identiﬁed late effects in national hospital registries
covering the period 1977–2012. Detailed treatment information was available for 46% of the survivors. The disease-speciﬁc rates of
hospitalization of survivors and of 152,231 randomly selected population comparisons were used to calculate standardized
hospitalization rate ratios (SHRRs) and absolute excess risks (AERs). During 5,500 person-years of follow-up, 501 5-year survivors had
a ﬁrst hospital contact yielding a SHRR of 2.3 (95% CI 2.1–2.6) and a corresponding AER of 52 (95% CI 44–60) per 1,000 person-
years. The highest relative risks were for diseases of blood and blood-forming organs (SHRR 3.8; 95% CI 2.7–5.4), endocrine diseases
(3.6 [3.1–4.2]), circulatory system diseases (3.1 [2.5–3.8]), and diseases of the nervous system (3.0 [2.6–3.3]). Approximately 60% of
the excess new hospitalizations of survivors were for diseases of the nervous system, urinary system, endocrine system, and bone
and soft tissue. The relative risks and AERs were highest for the survivors most intensively treated. Survivors of neuroblastoma have a
highly increased long-term risk for somatic late effects in all the main disease groups as compared to background levels. Our results
are useful for counseling survivors and should contribute to improving health care planning in post-therapy clinics.
Introduction
Neuroblastoma is the commonest extracranial solid cancer in
childhood and the commonest cancer in infancy, accounting
for 8–10% of childhood cancers.1 In the Nordic countries, the
5-year survival after neuroblastoma increased from 61% in
1999–2001 to 80% in 2005–2007,2 although wide variations
were seen by both age and stage of disease at diagnosis.2,3 To
attain the current survival rates, a high proportion of the sur-
vivors were exposed to intensive radiation and highly toxic
chemotherapeutic compounds;4,5 there is thus mounting
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concern about late effects, most of which become clinically
evident years after the children have been cured of their
cancer.6–10 Neuroblastoma is a relatively rare disease, with
poor survival before 1990,11 especially for high risk patients,
and long follow-up is required to detect possible late effects.6
Information about late effects in survivors of this tumor is
therefore sparse.
In the largest study on late effects in neuroblastoma survi-
vors to date,12 conducted within the North American Child-
hood Cancer Survivor Study, the relative risk for selected
chronic health conditions in neuroblastoma survivors diag-
nosed between 1970 and 1986 was eight times higher than in
their siblings, and the 20-year cumulative incidence of overall
chronic health conditions was 41%. The most prevalent condi-
tions involved the neurological, sensory, endocrine, and mus-
culoskeletal systems. Survivors who received multimodality
therapy were more than twice as likely to have a chronic
health condition than those treated by surgery only.12 These
ﬁndings were, however, based on self-reports, and treatment
protocols have further lengthened survival since 1986.13 Clini-
cal trials have improved and sustained cure rates with less
exposures in low and intermediate risk patients, and improved
cure rates for high risk patients using multimodality therapy,
including high-dose chemotherapy, targeted radiotherapy and
immunotherapy.
To fully understand the health risks associated with the
disease and its treatment, we studied 5-year neuroblastoma
survivors in four Nordic countries identiﬁed from nationwide,
population-based cancer registries dating back to the 1940s
and 1950s; late effects were identiﬁed as medically veriﬁed dis-
charge diagnoses in national hospital registries. Using popula-
tion comparisons as the reference, we assessed the risks for
somatic disease in all organ systems from information on hos-
pital visits. We had information on treatment from clinical
registries for 46% of the survivors.
Methods
The neuroblastoma cohort is a subcohort of the Nordic Adult
Life after Childhood Cancer in Scandinavia (ALiCCS) study
(www.aliccs.org), which comprises 33,576 individuals in Den-
mark, Finland, Iceland, and Sweden in whom cancer was
diagnosed before they were aged 20 between the start of the
cancer registries in the 1940s and 1950s and December
31, 2008 (Finland, 1971–2008).14,15 Of the 33,576 cancer
patients, 1,562 had neuroblastoma (Figure S1).
As previously described in greater detail,10 ﬁve comparison
subjects with no cancer diagnosed before the age of 20, who
were alive in the year of diagnosis of cancer in the corre-
sponding survivor and of the same sex, age, and country
(Denmark, Finland and Iceland) or county (Sweden) of resi-
dence, were randomly selected from the national population
registries, for a total of 167,712 individuals. All had to be alive
at or born after the start of centralized registration of residents
in each country (Iceland, 1955; Denmark and Sweden, 1968;
Finland, 1971). Information on vital status and emigration
during follow-up was also retrieved from these registries.
Main exclusion criteria were: a diagnosis of ganglioneuroma,
being diagnosed with more than one primary cancer before
the age of 20, having died or emigrated before the start of the
hospital registries, a diagnosis of chromosome abnormalities,
or less than 5 years of follow-up. After exclusions, there were
721 5-year neuroblastoma survivors and 152,231 comparisons
for analysis (further details in Figure S1).
Information on treatment from clinical registries based on
medical charts (Figure S1) was available for a subcohort of
332 (46%) of the 721 survivors,3,16–18 of whom 71 were trea-
ted with high-dose chemotherapy with autologous stem-cell
transplant (ASCT), 149 with chemotherapy irradiation
surgery, 103 by surgery only, and 9 received no treatment
(Table 1, footnote).
For all study subjects, we identiﬁed all hospital admissions
and outpatient visits (referred to as “ﬁrst hospital contacts”)
with a primary or supplementary diagnosis in the nationwide
hospital registries. These registries contain information on all
hospital admissions for somatic disease (since 1964 in Sweden,
1975 in Finland, 1977 in Denmark, and 1999 in Iceland),
including outpatient visits since 1995 in Denmark and 2001 in
Sweden (Table 2, footnote).15 We grouped the diagnoses into
ten main diagnostic groups (Table 3, footnote) and 104 dis-
ease-speciﬁc subcategories according to the International Clas-
siﬁcation of Diseases (ICD) (Table 3), with ICD-7, ICD-9, and
ICD-10 codes adapted to ICD-8 codes to the extent possible
(Table S1).
Statistical analysis
We used the Kaplan–Meier estimator to estimate the survival
probability of all 1,443 neuroblastoma patients according to
period of diagnosis, with time since diagnosis as the underlying
timescale. The end of follow-up was January 1, 2010, for Den-
mark, Sweden, and Finland and January 1, 2009, for Iceland.
What’s new?
Recent decades have seen great gains in neuroblastoma survival, but as people live longer after treatment, more long-term
complications emerge. Here, the authors investigated how often late effects afﬂicted 5-year neuroblastoma survivors. They
found that in the years after treatment, neuroblastoma survivors went to the hospital 2.5 times as often as the general
population. They saw the highest increases among patients who had high-dose chemotherapy with autologous stem cell
transplant. In addition, the cumulative incidence of somatic disease did not appear to plateau over time. Life-long follow up
will ensure timely diagnosis and treatment of these late effects.
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Follow-up for hospital contacts started 5 years after the date
of diagnosis (corresponding date for comparison subjects) or the
start of the hospital registers, whichever occurred later. Follow-
up ended on date of death, emigration, or end of the study
(Iceland: December 31, 2008; Sweden: December 31, 2009; Den-
mark: October 31, 2010; Finland: December 31, 2012), whichever
occurred ﬁrst. Both primary and supplementary diagnoses were
included. If a person had more than one hospital contact for a
disease subcategory, only the ﬁrst record was retained. The risk
for a ﬁrst hospital contact was estimated for each of the 104 dis-
ease subcategories and for the ten main diagnostic groups; for
each person, the total number of hospital contacts equalled the
sum of ﬁrst hospital contacts for the 104 disease subcategories.
Standardized hospitalization rate ratios (SHRR) were calculated
as the observed number of ﬁrst hospital contacts among neuro-
blastoma survivors in a given disease category divided by the
expected number derived from the appropriate country, sex-,
age-, and calendar period-speciﬁc hospitalization rates of the
comparison cohort. The 95% conﬁdence intervals (CIs) of the
SHRRs were estimated with Fieller’s theorem, on the assumption
that the observed number of ﬁrst hospital contacts followed a
Poisson distribution. The absolute excess risks (AERs) of survi-
vors for a ﬁrst hospital contact were calculated as the difference
between the observed and expected hospitalization rates for a
particular disease category per 1,000 person-years of follow-up.
To test the robustness of the overall results, we conducted
a sensitivity analysis restricted to neuroblastoma survivors
diagnosed 5 years before the start of the national patient regis-
tries until the end of the study period.
We used the Aalen-Johansen estimator to estimate the
cumulative incidence of ﬁrst hospital contacts for each of the
ten main diagnostic groups and for all groups combined, tak-
ing the competing risk for death into account and time since
diagnosis as the underlying timescale.19 For this analysis, we
used the comparisons directly matched to the cohort of neu-
roblastoma survivors by country, sex, age and calendar period
(n = 3,511).
To estimate the effects of sex, age at diagnosis, and treat-
ment on the hazard for a ﬁrst hospital contact, we conducted
a multivariable analysis with these covariates within the clini-
cal subcohort of 5-year survivors for whom information on
treatment was available. A Cox proportional hazards model
was used to estimate the cause-speciﬁc hazard ratios (HRs) of
a ﬁrst hospital contact with follow-up starting 5 years after
neuroblastoma diagnosis and with time since diagnosis as the
underlying time scale and censoring for the competing event,
death.20 The reference groups were male patients for sex and
patients treated by surgery only for treatment.
We used SAS software versions 9.3 and 9.4 to determine
the relative (SHRR) and absolute (AER) risks. To estimate the
probability of survival, the cumulative incidence of hospitali-
zations and for the within-cohort analysis, we used the statis-
tical software R version 3.3.2 and the packages survival, etm
and timereg.
The design of the ALiCCS study was approved by the national
bioethics committees, the data protection authorities, or the
national institutes for health and welfare in the respective coun-
tries (Denmark: 2010–41-4334, Finland: THL/520/5.05.00/2016,
Table 2. Observed and expected numbers of first hospital contacts for a disease in any of the 10 main diagnostic groups among 721 5-year
survivors of neuroblastoma in the Nordic countries by attained age
SHRR (95% CI)
Hospitalization rate per 1,000 person-years
AER (95% CI)
Observed Expected Observed Expected
Total no. of people ever hospitalized 501 214.9 2.3 (2.1–2.6) 91 39 52 (44–60)
Total no. of first hospitalizationsa,b 1,789 730.7 2.5 (2.3–2.6) 160 65 94 (87–102)
Attained age (years)
<10 391 103.4 3.8 (3.4–4.2) 209 55 154 (133–175)
10–19 652 225.3 2.9 (2.7–3.1) 150 52 98 (87–110)
20–29 398 201.1 2.0 (1.8–2.2) 134 67 66 (53–79)
30–39 230 124.8 1.8 (1.6–2.1) 159 86 73 (52–94)
40–49 81 56.0 1.5 (1.2–1.8) 175 121 54 (16–92)
50–59 36 18.7 1.9 (1.4–2.7) 358 186 172 (55–289)
60–69 1 1.35 0.7 (0.1–5.3) 185 250 −64 (−427–298)
aHospital discharge diagnoses available from hospital registries and classified according to the International Classification of Diseases: Denmark
1977–2010 (ICD-8 in 1977–1993, ICD-10 since 1994); Finland 1983–2009 (ICD-8 in 1983–1986, ICD-9 in 1987–1995, and ICD-10 since 1996); Iceland
1999–2008 (ICD-10) and Sweden 1964–2009 with stepwise inclusion of counties between 1964 and 1987 and national coverage since 1987 (ICD-7 in
1964–1968, ICD-8 in 1969–1986, ICD-9 in 1987–1996, and ICD-10 since 1997). Information on outpatient visits available in Denmark since 1995 and
in Sweden since 2001. bFor participants with more than one hospital contact for a particular disease category, only the first record in the 104 disease
categories was retained. The relative risk was estimated for each of the 104 disease categories and for the ten main diagnostic groups by adding the
numbers of first hospital contacts within each disease category. Thus, for each person, the total number of hospital contacts equalled the sum of hospi-
tal contacts for one of the 104 disease subcategories.
Abbreviations: SHRR, standardized hospitalization rate ratio; CI, confidence interval; AER, absolute excess risk per 1,000 person-years.
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Table 3. Standardized hospitalization rate ratios (SHRRs) and absolute excess risks (AERs) of 721 5-year survivors of neuroblastoma in each of
the 104 specific somatic disease categories for which there were at least five* observations (leaving 77 disease categories) including
diagnoses for both inpatient and outpatient visits**
Main diagnostic group No. of ﬁrst hospital contacts
Disease category Observed Expected SHRR (95% CI)
AER per 1,000
person-years (95% CI)
Infectious and parasitic diseases
Intestinal infectious diseases 27 137 20 (16–29) 12 (03–21)
Sepsis 12 15 83 (46–147) 10 (03–16)
Erysipelas 9 23 39 (20–76) 06 (01–11)
Other bacterial diseases 9 23 39 (20–75) 06 (01–11)
Other viral diseases with exanthem 7 49 14 (07–30) 02 (–03–07)
Infectious hepatitis, HIV infections (only in ICD-
9 and -10), and other viral diseases
44 141 31 (23–42) 28 (16–40)
Syphilis and other venereal diseases 9 107 08 (04–16) – 02 (–07–04)
Mycoses 9 50 18 09–34) 04 (–02–09)
Other infectious and parasitic diseases 6 41 15 (07–33) 02 (–03–06)
Endocrine diseases, nutritional deficiencies,
and other metabolic diseases
Diseases of the thyroid gland 33 50 66 (47–94) 25 (15–36)
Diabetes mellitus 10 75 13 (07–25) 0.2 (–0.3–0.8)
Pituitary hypofunction 21 06 357 (226–565) 18 (10–26)
Ovarian dysfunction 10 17 61 (32–113) 07 (02–13)
Testicular dysfunction 6 01 675 (274–1664) 05 (01–10)
Disorders of other endocrine organs 25 41 61 (41–90) 19 (10–28)
Other metabolic disorders 31 26 119 (83–170) 26 (16–35)
Male sterility 11 22 51 (28–92) 08 (02–14)
Abnormal menstruation 19 111 17 (11–27) 07 (–01–15)
Female infertility 11 67 17 (09–30) 04 (–02–10)
Other disorders of the female reproductive
system
14 96 15 (09–25) 04 (–03–11)
Diseases of the blood and blood-forming
organs
Anemias 19 33 59 (37–92) 14 (06–22)
Coagulation defects, purpura, and other
hemorrhagic conditions
10 28 36 (19–68) 07 (01–12)
Diseases of the nervous system and sense
organs
Epilepsy 30 658 46 (32–65) 21 (12–31)
Migraine and other diseases of the brain and
spinal cord
30 1071 28 (20–40) 18 (08–27)
Diseases of the nerves and peripheral ganglia 34 925 37 (26–52) 23 (12–33)
Inflammatory and other diseases of the eye 62 305 20 (16–26) 29 (15–44)
Inflammatory diseases of the ear 45 194 23 (17–31) 24 (12–36)
Other diseases of the ear and deafness 40 84 48 (35–65) 29 (17–40)
Paralytic syndromes 34 09 366 (256–524) 30 (20–41)
Diseases of the circulatory system
Hypertensive disease 16 40 40 (25–66) 11 (04–18)
Pericardial, myocardial, and endocardial
disease
6 135 44 (20–100) 04 (0–08)
(Continues)
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Table 3. Continued
Main diagnostic group No. of ﬁrst hospital contacts
Disease category Observed Expected SHRR (95% CI)
AER per 1,000
person-years (95% CI)
Valvular disease (non-rheumatic) 6 06 95 (42–214) 05 (01–09)
Heart failure 10 08 127 (67–239) 08 (03–14)
Conduction disorders 9 46 20 (10–38) 04 (–01–09)
Cerebrovascular disease 10 21 47 (25–89) 07 (02–13)
Diseases of the arteries, arterioles, and
capillaries
7 16 45 (21–95) 05 (0–10)
Venous and lymphatic disease 16 110 15 (09–24) 05 (–03–12)
Diseases of the respiratory system
Acute upper respiratory infections 52 317 16 (13–22) 19 (06–32)
Other disorders of the upper respiratory tract 74 538 14 (11–17) 20 (03–36)
Pneumonia 32 103 31 (22–44) 20 (10–30)
Abscess of lung and pyothorax 6 087 69 (31–155) 05 (0–09)
Bronchitis and emphysema 11 419 26 (15–48) 06 (0–12)
Asthma 21 2097 10 (07–15) 0 (–08–08)
Respiratory failure 13 060 218 (124–385) 11 (05–18)
Other diseases of the respiratory system 5 064 78 (32–191) 04 (0–08)
Diseases of the digestive organs
Diseases of the teeth and supporting
structures
34 1070 32 (23–45) 21 (11–32)
Other diseases of the oral cavity and salivary
glands
6 342 18 (08–39) 02 (–02–07)
Diseases of the esophagus 10 423 24 (13–44) 05 (0–11)
Diseases of stomach and duodenum 24 823 29 (20–44) 14 (06–23)
Appendicitis 19 2148 09 (06–14) – 02 (–01–06)
Hernia of the abdomal cavity 14 1089 13 (08–22) 03 (–04–09)
Non-infective enteritis and colitis 8 748 11 (05–21) 00 (–05–05)
Paralytic ileus and intestinal obstruction 20 114 175 (111–276) 17 (09–25)
Diseases of the anal and rectal regions 6 521 12 (05–26) 01 (–04–05)
Diseases of the peritoneum 8 083 97 (48–196) 06 (01–11)
Other diseases of the digestive system 38 1427 27 (19–37) 22 (11–33)
Diseases of the liver 9 143 63 (32–122) 07 (02–12)
Diseases of the gallbladder and biliary ducts 10 779 13 (07–24) 02 (–04–08)
Diseases of the urinary system and genital
organs
Glomerular diseases 7 14 49 (23–103) 05 (0–10)
Chronic kidney disease 18 16 112 (70–179) 15 (07–22)
Urolithiasis 8 34 24 (12–47) 04 (–01–09)
Obstructive uropathy 11 15 74 (40–134) 09 (03–14)
Infections of the urinary system 40 141 28 (21–39) 24 (12–35)
Other and unspecified disorders of the urinary
system
50 43 118 (89–156) 43 (30–56)
Hydrocele and spermatocele 5 15 33 (14–81) 0.3 (–01–07)
Other diseases of the male genital organs 17 113 15 (09–24) 05 (–02–13)
Chronic cystic disease and other diseases of
the breast
19 77 25 (16–39) 10 (02–18)
(Continues)
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Iceland: VSN 10–041 & VSN 12–084-V1 and Sweden: Ö
10–2010, 2011/19).
Results
Table 1 shows the main characteristics of all children with
neuroblastoma, 5-year survivors, and population comparisons.
The basic cohort comprised 1,443 individuals, of whom
721 survived for 5 years or more. Information on treatment
was available for 332 (46%) of all 5-year survivors.
Figure 1 shows the 5-year survival of children with neuro-
blastoma by period of diagnosis from before 1980 and up
until 2004. Survival increased signiﬁcantly and steadily over
time: the 5-year survival of children with neuroblastoma diag-
nosed in 1980–1989 was 53% (95% CI 47–59), and that of
cases diagnosed in 2000–2004 was 68% (95% CI 63–74).
The 5-year survivors were followed in the national hospital
registries for a median of 13.4 years (range, 0.08–42), yielding
5,500 person-years of observation. A total of 501 survivors
had a ﬁrst hospital contact, while 215 would have been
expected, giving a signiﬁcantly increased relative risk of 2.3
(95% CI 2.1–2.6) (Table 2), with no apparent difference
between males (SHRR 2.3 95% CI 2.0–2.6) and females
(SHRR 2.4 95% CI 2.1–2.7). The AER of survivors was 52 per
1,000 person-years (95% CI 44–60). Thus, for each additional
year of follow-up, approximately ﬁve of every 100 5-year sur-
vivors had a ﬁrst hospital contact for a new disease beyond
background levels.
The relative risk for a ﬁrst hospital contact for a disease in
any of the ten main diagnostic groups was increased at all
ages, even for survivors approaching 60 years. However, the
risk decreased with increasing age, from 3.8 (95% CI 3.4–4.2)
for survivors below 10 years to 1.9 in survivors aged
50–59 years (Table 2), as did the AER, except for patients
aged 50–59 years, who had an AER of 172 for a ﬁrst hospital
contact per 1,000 person-years (95% CI 55–289).
The relative risks for a ﬁrst hospital contact for diseases
in all ten main diagnostic groups as well as for any disease
were statistically signiﬁcantly increased among survivors
(SHRR 2.5; CI 95% 2.3–2.6) (Figure 2(a)). The risks of sur-
vivors for diseases in nine of the ten main diagnostic
groups were more than double those of comparisons. The
highest relative risks were seen for diseases of blood and
blood-forming organs (SHRR 3.8; 95% CI 2.7–5.4), endo-
crine organs (SHRR 3.6; 95% CI 3.1–4.2), the circulatory
system (SHRR 3.1; 95% CI 2.5–3.8), and the nervous system
(SHRR 3.0; 95% CI 2.6–3.3). The increases were even
higher for the group of survivors treated with high-dose
chemotherapy with ASCT (Figure 2b).
Table 3. Continued
Main diagnostic group No. of ﬁrst hospital contacts
Disease category Observed Expected SHRR (95% CI)
AER per 1,000
person-years (95% CI)
Inflammatory diseases of the female pelvic
organs
26 153 17 (12–25) 10 (01–19)
Endometriosis 5 31 16 (07–38) 02 (–02–06)
Non-inflammatory disorders of the female
genital tract
26 161 16 (11–24) 09 (0–18)
Diseases of the skin and subcutaneous tissue
Infections of the skin and subcutaneous tissue 27 123 22 (15–32) 13 (04–23)
Other inflammatory conditions of the skin and
subcutaneous tissue
33 244 14 (10–19) 08 (–03–18)
Disorders of skin appendages (hair, nails,
sweat glands)
18 121 15 (09–24) 05 (–02–13)
Other disorders of the skin and subcutaneous
tissue
55 77 72 (55–94) 44 (30–57)
Diseases of the bone, joints, and soft tissue
Arthritis and rheumatism 21 143 15 (10–23) 06 (–02–14)
Osteomyelitis and other diseases of the bone
and joints
138 494 28 (24–33) 87 (64–110)
Other diseases of the musculoskeletal system 86 321 27 (22–33) 54 (36–72)
*To provide a complete and comprehensive overview of all diseases with an observed number 5. Note that some CI’s are very wide and thus should be
interpreted with caution.
**Including outpatient visits since 1995 in Denmark and 2001 in Sweden.
We did not include the following ICD sections: second malignant neoplasms, as we excluded all subjects with more than one cancer before age 20 from
the survivor group and all subjects with a primary cancer before age 20 from the comparisons; mental disorders, as these are reported in a separate
registry; symptoms and ill-defined diseases, as these were regarded not specific enough for solid conclusions; and injuries and violence, as these con-
ditions are of external origin. We did not include the sections on deliveries and reproductive difficulties, as these require special consideration and will
be dealt with in a separate publication.
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The analysis limited to 654 survivors with a full hospital
history did not show any notable difference for the total num-
ber of ﬁrst hospital contacts for any disease (RR 2.6; CI
95% 2.5–2.7).
Diseases of the nervous system and sense organs (AER
17 per 1,000 person-years; 95% CI 14–20), the urinary system
and genital organs (AER 13; 95% CI 10–15), endocrine dis-
eases and nutritional deﬁciencies (AER 13; 95% CI 10–15),
and diseases of bone and soft tissue (AER 12; 95% CI 10–15)
were the reasons for almost 60% of all excess new hospital
contacts (Figure 2a; Table 3). The disease pattern was similar
for the 71 survivors treated with high-dose chemotherapy with
ASCT and for the 149 survivors treated with chemotherapy
irradiation, with slight variations. For those treated by sur-
gery only, diseases of the nervous system, infections, diseases
of the skin, and diseases of bone and soft tissue were the rea-
sons for 65% of all excess new hospital contacts, whereas the
AER for hospitalization for endocrine diseases was not signiﬁ-
cantly increased (AER 1; 95% CI –4–6) (Figure 2b).
Figure 3 shows that 69% (95% CI 65.0–72.6) of all 5-year
survivors and 45% (95% CI 43.0–47.0) of the population com-
parisons had had at least one ﬁrst hospital contact 20 years
after diagnosis; after 40 years, the proportions were 89% (95%
CI 86.1–92.7) and 79% (95% CI 77.1–81.7), respectively.
For the subcohort of survivors for whom information on
treatment was available, the cumulative incidence of a ﬁrst
hospital contact was signiﬁcantly higher than that for compar-
isons 15 years after diagnosis. The highest cumulative risk was
seen for survivors treated with high-dose chemotherapy with
ASCT, of whom 79% had had a ﬁrst hospital contact, as
compared with 41% of comparisons. The cumulative risks for
diseases in the other main diagnostic groups are presented in
Figure S2.
The within-cohort analysis of 5-year survivors for whom
information on treatment was available showed no signiﬁcant
effect of sex (HR 1.00; 95% CI 0.76–1.31) or age at diagnosis
(HR 1.04; 95% CI 0.99–1.08). The cause-speciﬁc hazard of
patients treated with chemotherapy irradiation (HR 1.00; 95%
CI 0.73–1.37) was not signiﬁcantly different from that of
patients treated by surgery only (reference group). The hazard
for a ﬁrst hospitalization of patients treated with high-dose che-
motherapy with ASCT was signiﬁcantly higher than that of
patients treated by surgery only (HR 1.54; 95% CI 1.06–2.26).
Discussion
This population-based study of 721 5-year neuroblastoma sur-
vivors in the Nordic countries illustrates the pattern of
somatic late effects serious enough to require a hospital con-
tact. The survivors had a hospital contact for a new somatic
disease 2.5 times as often as the general population, and the
increased risk was higher for the subgroup of survivors who
received the most intensive treatment (RR 5.8; 95% CI
5.0–6.8). Both the cancer and its treatment may adversely
affect virtually any organ or body system; however, survivors
who had been treated with high-dose chemotherapy with
ASCT had the highest relative and absolute excess risks for
somatic diseases in all ten main diagnostic groups.
Before the mid-1990s, almost no children in the Nordic
countries with disseminated neuroblastoma (stage IV) sur-
vived. Those who survived had either been diagnosed as
infants (<12 months of age) or had localized disease. Their
treatment included surgery and/or radiotherapy. In few cases,
i.e., in very young children or infants, no treatment was given
awaiting spontaneous tumor regression. In the late 1980s, the
Nordic countries (except from Finland) joined the European
Neuroblastoma Study Group (ENSG) and participated in
ENSG protocols investigating the role of cis-retinoic acid
(ENSG4) and that of intensiﬁed induction chemotherapy
(COJEC vs. OPEC/OJEC, ENSG5, 21). Nevertheless, survival
of disseminated neuroblastoma ﬁrst improved after the intro-
duction of high dose chemotherapy (melphalan +/− busulfan
or carboplatin) followed by autologous stem cell rescue in the
mid-1990s. Irradiation of the primary tumor bed was only
performed in case of inoperable tumor or macroscopic tumor
rest. Inoperable localized tumors received preoperative che-
motherapy (OPEC/OJEC22) prior to tumor resection and/or
radiotherapy. Finland used its own protocols, which included
total body irradiation (TBI) since 1987 and high dose chemo-
therapy with stem cell rescue since 1982.23 TBI has not been
used in Denmark, Iceland and Sweden.
The Nordic countries are now part of the SIOPEN–NB
group (except Finland). Thus, since the early 2000s high-risk
neuroblastoma patients have been treated according to the
SIOPEN-NB protocols. Today, the treatment of disseminated/
Figure 1. Survival curves for the basic cohort of 1,143 children with
neuroblastoma, by period of diagnosis. [Color ﬁgure can be viewed
at wileyonlinelibrary.com]
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high risk neuroblastoma consists of intensive induction treat-
ment, surgery of the primary tumor, high dose chemotherapy
with autologous stem cell rescue, radiotherapy to the ﬁeld of
the primary, cis-retinoic acid and in more recent time also
anti-GD2 antibody.
Localized or metastatic disease with favorable tumor charac-
teristics in young children under the age of 1–1½ year has the
ability of spontaneous regression, whereas older children with
localized disease are treated with surgery only and/or with che-
motherapy. Children with disseminated disease or unfavorable
tumor characteristics require very intensive multimodal
treatment including high-dose chemotherapy, targeted radio-
therapy and immunotherapy. Contemporary regimens, which
incorporate chemotherapeutic agents and treatment modalities
used for many decades, have evolved to improve relapse-free
survival (as shown in Figure 1) and reduce long-term toxicity.
Despite that, more than 50% of patients need intensive treat-
ment that may cause unavoidable long-term toxicity.
The cumulative incidence of adverse health conditions in sur-
vivors increased with time and did not appear to plateau during
the follow-up period. The cumulative incidence of somatic dis-
eases was much higher in survivors than comparisons at an
Figure 2. (a and b) Standardized hospitalization rate ratios (SHRRs) and absolute excess risks (AERs) per 1,000 person-years of follow-up for
ﬁrst hospital contacts for any disease and diseases in ten main diagnostic groups among 5-year survivors of neuroblastoma diagnosed from
1951–2008 and of the subcohort of survivors diagnosed from 1980–2008 for whom information on treatment was available, by treatment
group.
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earlier stage of life, both for overall somatic diseases as well as
for speciﬁc main diagnostic groups, implying premature aging or
frailty in survivors24 (Figure 3). The increases in relative and
absolute excess risks for a hospital contact were higher in the
youngest group of survivors (<10 years) and decreased with time
since diagnosis. Although variations were seen by age and treat-
ment, the ﬁndings imply that the majority of neuroblastoma sur-
vivors are at substantial risk for somatic late effects and that the
risk remains increased throughout life. For survivors treated by
surgery only, the overall risk was moderate.
Although little has been known about treatment-induced late
effects in neuroblastoma survivors until today, it was evident that
this group of survivors had an excess risk for long-term
morbidity25–30 Oefﬁnger et al. showed that 416 5-year neuroblas-
toma survivors included in the Childhood Cancer Survivor Study
had twice the risk of reporting at least one adverse chronic
health condition than siblings and an almost ﬁve times greater
risk for a severe or life-threatening condition.9 Laverdiére
et al. found that the risk of neuroblastoma survivors for a
chronic health condition primarily involving the neurological,
Figure 2. Continued [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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sensory, endocrine, and musculoskeletal systems was almost
eight times higher than that of siblings.12 Kurt et al. found
a relative risk for self-reported hospitalization of 1.7 for
neuroblastoma survivors as compared with the population
rates derived from a United States National Hospital Discharge
Survey covering the period 1992–2005.31 This ﬁnding is fairly
Figure 3. Cumulative incidence of ﬁrst hospital contacts for any disease and for four main diagnostic groups among 5-year survivors and for
the subcohort for whom information on treatment was available, by time since cancer diagnosis and the corresponding date for comparisons.
Note, that beyond 40–50 years from time of diagnosis for all 5-year survivors there are few cases, and correspondingly beyond 20 years from
time of diagnosis in the treatment subgroups. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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consistent with ours, despite differences in the source of hos-
pitalizations and the period of diagnosis (1970–1986 in
the Childhood Cancer Survivor Study; 1951–2008 in
ALiCCS).
Studying late effects in long-term neuroblastoma survivors,
the majority of the study subjects will be survivors of low-
stage tumors. According to Fox et al.4 50–60% of all children
with neuroblastoma included in the Childhood Cancer Survi-
vor Study and diagnosed in the 1970s had metastatic disease
(stage IV) at presentation, but less than 15% of these patients
survived for 5 years. Thus, 75% of the survivor cohort were
presumably survivors of stage I or II disease,4 which would
result in underestimation of the risk for late effects of patients
with intermediate and high-risk neuroblastoma. The Nordic
survivors who were treated with high-dose chemotherapy with
ASCT and all diagnosed between 1990 and 2008 had a relative
risk for somatic disease of 5.8 as compared with 2.6 in the
subgroup treated with chemotherapy irradiation. This high
relative risk implies that intensive treatment of high-risk
patients since the 1990s has improved survival but results in
more late effects.
Disorders of the nervous system accounted for 18% of the
absolute excess risk for any disorder in 5-year survivors and
for 21–25% in the subgroups for whom information on treat-
ment was available, with AERs ranging from 14 per 1,000 sur-
vivors (95% CI 4–24) for those treated by surgery only to
79 (95% CI 51–107) for those treated with high-dose chemo-
therapy with ASCT. The increased risk for late effects of
patients treated by surgery only is probably due to the fact
that the tumor can arise close to the spine and grow into the
spinal canal, causing medullary compression (dumbbell
tumor), resulting in permanent neurological deﬁcits.
We used hospital-based diagnoses as markers of somatic
diseases. This increased the validity of the diagnostic informa-
tion but may have overlooked less severe late effects treated in
the primary health care system or in outpatient clinics. As
information on outpatient visits was available only in Den-
mark and Sweden and only recently, the overall burden of
somatic disease experienced by neuroblastoma survivors is
probably underestimated. As such underregistration can be
assumed to affect survivors and comparisons equally, thus, it
is not expected to affect the risk estimates. However, some
diagnoses, such as cisplatin-induced hearing impairment, may
not be systematically registered by the treating physician since
hearing loss is commonly seen after treatment with cisplatin.
Another possible limitation is that survivors of childhood can-
cer are likely to be followed more intensively in the health
care system than the average population, so that any health
problems may be detected at an earlier stage than in
comparisons.
Our study was population-based, and we had randomly
selected comparisons, data from high-quality health registries,
and information on treatment for a large sample of long-term
survivors. Thus, we consider that our results are applicable to
children treated for neuroblastoma in other countries with
similar health care systems. A more thorough evaluation of
this group of survivors would include medical record abstrac-
tion to obtain detailed information on drugs and doses, radio-
therapy and radiation ﬁelds, surgical procedures, as well as
clinical examinations.
In conclusion, we found that neuroblastoma survivors had
a much higher long-term risk for late somatic effects in all
main diagnostic groups than a background population of sim-
ilar age and matched on sex. The increased relative risk was
seen for all treatment groups but was most pronounced for
the survivors who had been treated most intensively.
Clinicians in primary and secondary health care should be
aware that survivors of neuroblastoma are hospitalized more
than twice as often as the general population for a wide range
of serious somatic conditions. The excess risk could be trans-
lated into nine new excess hospital contacts for every 100 sur-
vivors followed for a year. Life-long follow-up in late effect
clinics is highly recommended to ensure timely diagnosis and
management of emerging and established late effects in this
vulnerable group of patients.
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